Category Archives: compliance

Video: Should Pharmacies Be Held to the Same FDA Standards?

By Reid Paul | Published: October 10, 2012
Also posted in Corporate Responsibility, FDA, Manufacturing, News, Strategy | 1 Comment

SciClone Pharmaceuticals: Selling Specialty Drugs in China

By Ben Comer | Published: October 1, 2012
US-based SciClone Pharmaceuticals has built its business around selling specialty drugs in China. Companies like Sanofi and Pfizer, despite their own in-country resources, have partnered with SciClone and are achieving better returns, according to SciClone CEO Friedhelm Blobel.
Also posted in Biotech, Emerging Markets, Global, IP, Legal, Manufacturing, People, Regulatory, Sales, Strategy, healthcare, pricing | Tagged , , | 1 Comment

Forest Labs Hit with Bad Ad Tattle

By Ben Comer | Published: August 7, 2012
Forest Labs has had a tough time with regulators over the last two years. The company’s sales reps can’t seem to stop breaking the law. The latest offense, which generated an Untitled Letter from the Office of Prescription Drug Promotion (OPDP), was brought to light through OPDP’s Bad Ad program, which encourages physicians to report on [...]
Also posted in Corporate Responsibility, FDA, Legal, Marketing, Regulatory, Sales | Tagged , , , , , , , | Leave a comment

Bristol-Myers Squibb's Summertime Blues

By Ben Comer | Published: August 7, 2012
The sun was shining, savory scents were floating out from the grill, the lemonade was mixed and the table was set. But then dark clouds blew in and settled overhead. Bristol-Myers Squibb’s (BMS) picnic got rained out this summer. One element of the rain out was forecasted long ago; Plavix, the multibillion dollar [...]
Also posted in Advertising, Biotech, Deals, FDA, Legal, Marketing, R&D, Regulatory, Safety, Sales, Strategy, pricing | Tagged , , , , , | Leave a comment

Comply or Die: Introducing GSK's New Corporate Integrity Agreement

By Ben Comer | Published: July 6, 2012
Big pharma talks a lot about the changing business model and placing a new emphasis on patients, but the fact remains that quantity of medicines sold, not quality of care provided, is how to get paid (and how to keep investors happy). Despite its egalitarian trappings, the healthcare “ecosystem” is still dominated by the [...]
Also posted in Agency Insight, Corporate Responsibility, Legal, Marketing, Regulatory, Sales, Strategy | Tagged , , , , , , , , , , | Leave a comment